ADPT President and COO Julie Rubinstein Sells $302K of Stock

Adaptive Biotechnologies Corporation President and COO Julie Rubinstein sold 11,881 shares of the company on October 21, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The transaction was executed at an average price of $25.41 per share, totaling approximately $301,877.20. This sale was carried out under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Rubinstein directly owns 377,802 shares of the company. It marks another scheduled sale for the executive following similar transactions earlier in the month.

ADPT Adaptive Biotechnologies Corporation

$25.33 ▲ +59.21% year to date

1M 3M YTD

Daily close · Oct 21, 2026

Inside Julie Rubinstein's ADPT Trade

The planned sale covered 11,881 shares at $25.41 apiece, trimming Rubinstein's holding by about 3.05%. This trade follows four similar pre-arranged sales executed by Rubinstein between October 13 and October 16, 2026, where she also offloaded blocks of 11,881 shares each. After the latest transaction, her direct stake in the diagnostics and research firm stands at 377,802 shares.

Other Institutional Activity in Adaptive Biotechnologies

Viking Global Investors, L.P. maintained a steady stake of 29,993,708 shares valued at about $759,740,621. Shaw D.E. & Co., Inc. grew its holdings by 2,660,252 shares, ending with 4,625,859 shares worth about $117,173,008. Westfield Capital Management Co LP trimmed its position by 1,168,845 shares, ending with 4,267,645 shares worth about $108,099,447.

Adaptive Biotechnologies Corporation Stock Holds Steady

Adaptive Biotechnologies recently traded around $24.42 on October 21, 2026, down about 3.6% from its event closing price of $25.33. The shares sit roughly 6.6% below their 50-day moving average of $26.13, yet remain 27.1% above their 200-day moving average of $19.22. The stock trades about 20.6% below its 52-week high of $30.74 and stands well above its 52-week low of $12.00.

Recent Earnings

Adaptive Biotechnologies posted $308,080,992 in trailing twelve month revenue alongside a negative basic earnings per share of $0.41. The company reported a net margin of -20.7% and a return on equity of -38.8% over the period, with year-over-year revenue growth coming in at 21.5%. Its next earnings release is scheduled for November 4, 2026.

Insider Buying and Selling at Adaptive Biotechnologies Corporation

Julie Rubinstein completed four prior sales in October 2026 under her trading plan, including selling 11,881 shares on October 13 at $25.50, 11,881 shares on October 14 at $25.68, 11,881 shares on October 15 at $25.61, and 11,881 shares on October 16 at $24.24.

Analysts Set New Price Targets

BTIG, Goldman Sachs, Guggenheim, and TD Cowen maintain Buy ratings on the stock, while Morgan Stanley holds an Equal-Weight rating. Overall, the company carries a strong buy recommendation from eight analysts with a mean price target of $29.81.

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation operates as a commercial-stage enterprise developing an immune medicine platform focused on diagnosing and treating various diseases. The Seattle-based firm uses proprietary chemistry, computational biology, and machine learning to decode the adaptive immune system for clinical applications.

Bottom Line

Insider transactions under pre-arranged trading plans offer routine insight into executive portfolio management without signaling sudden shifts in corporate direction. Market participants will look toward the upcoming earnings release on November 4, 2026, for further updates on financial progress.